The global market for Non-24-hour Sleep-wake Disorder Treatment was estimated to be worth US$ 480 million in 2023 and is forecast to a readjusted size of US$ 726.1 million by 2030 with a CAGR of 6.1% during the forecast period 2024-2030

Non-24-hour Sleep-wake Disorder Treatment - Market

Non-24-hour sleep-wake disorder (N24) is a circadian rhythm sleep disorder in which an individual's biological clock fails to synchronize to a 24-hour day. Instead of sleeping at roughly the same time every day, someone with N24 will typically find their sleep time gradually delaying by minutes to hours every day.

North American market for Non-24-hour Sleep-wake Disorder Treatment was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Non-24-hour Sleep-wake Disorder Treatment was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Europe market for Non-24-hour Sleep-wake Disorder Treatment was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global key companies of Non-24-hour Sleep-wake Disorder Treatment include Teva, Mylan, Nature’s Bounty, Otsuka Pharma (Pharmavite), Boiron, Miers Laboratories, Genexa, Homeocan and Clinigen Group, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Non-24-hour Sleep-wake Disorder Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Non-24-hour Sleep-wake Disorder Treatment by region & country, by Type, and by Application.

The Non-24-hour Sleep-wake Disorder Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-24-hour Sleep-wake Disorder Treatment.

Market Segmentation

Scope of Non-24-hour Sleep-wake Disorder Treatment - Market Report

Report Metric	Details
Report Name	Non-24-hour Sleep-wake Disorder Treatment - Market
Forecasted market size in 2030	US$ 726.1 million
CAGR	6.1%
Forecasted years	2024 - 2030
Segment by Type:	Prescription Drugs OTC
Segment by Application	Hospital Pharmacies Retail Pharmacies Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Teva, Mylan, Nature’s Bounty, Otsuka Pharma (Pharmavite), Boiron, Miers Laboratories, Genexa, Homeocan, Clinigen Group, Vanda Pharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Non-24-hour Sleep-wake Disorder Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Non-24-hour Sleep-wake Disorder Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Non-24-hour Sleep-wake Disorder Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Non-24-hour Sleep-wake Disorder Treatment - Market size in 2030?

Ans: The Non-24-hour Sleep-wake Disorder Treatment - Market size in 2030 will be US$ 726.1 million.

Who are the main players in the Non-24-hour Sleep-wake Disorder Treatment - Market report?

Ans: The main players in the Non-24-hour Sleep-wake Disorder Treatment - Market are Teva, Mylan, Nature’s Bounty, Otsuka Pharma (Pharmavite), Boiron, Miers Laboratories, Genexa, Homeocan, Clinigen Group, Vanda Pharma

What are the Application segmentation covered in the Non-24-hour Sleep-wake Disorder Treatment - Market report?

Ans: The Applications covered in the Non-24-hour Sleep-wake Disorder Treatment - Market report are Hospital Pharmacies, Retail Pharmacies, Other

What are the Type segmentation covered in the Non-24-hour Sleep-wake Disorder Treatment - Market report?

Ans: The Types covered in the Non-24-hour Sleep-wake Disorder Treatment - Market report are Prescription Drugs, OTC

1 Market Overview

1.1 Non-24-hour Sleep-wake Disorder Treatment Product Introduction

1.2 Global Non-24-hour Sleep-wake Disorder Treatment Market Size Forecast

1.3 Non-24-hour Sleep-wake Disorder Treatment Market Trends & Drivers

1.3.1 Non-24-hour Sleep-wake Disorder Treatment Industry Trends

1.3.2 Non-24-hour Sleep-wake Disorder Treatment Market Drivers & Opportunity

1.3.3 Non-24-hour Sleep-wake Disorder Treatment Market Challenges

1.3.4 Non-24-hour Sleep-wake Disorder Treatment Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Non-24-hour Sleep-wake Disorder Treatment Players Revenue Ranking (2023)

2.2 Global Non-24-hour Sleep-wake Disorder Treatment Revenue by Company (2019-2024)

2.3 Key Companies Non-24-hour Sleep-wake Disorder Treatment Manufacturing Base Distribution and Headquarters

2.4 Key Companies Non-24-hour Sleep-wake Disorder Treatment Product Offered

2.5 Key Companies Time to Begin Mass Production of Non-24-hour Sleep-wake Disorder Treatment

2.6 Non-24-hour Sleep-wake Disorder Treatment Market Competitive Analysis

2.6.1 Non-24-hour Sleep-wake Disorder Treatment Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Non-24-hour Sleep-wake Disorder Treatment Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-24-hour Sleep-wake Disorder Treatment as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Prescription Drugs

3.1.2 OTC

3.2 Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type

3.2.1 Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Non-24-hour Sleep-wake Disorder Treatment Sales Value, by Type (2019-2030)

3.2.3 Global Non-24-hour Sleep-wake Disorder Treatment Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital Pharmacies

4.1.2 Retail Pharmacies

4.1.3 Other

4.2 Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application

4.2.1 Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Non-24-hour Sleep-wake Disorder Treatment Sales Value, by Application (2019-2030)

4.2.3 Global Non-24-hour Sleep-wake Disorder Treatment Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Region

5.1.1 Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Region (2019-2024)

5.1.3 Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Region (2025-2030)

5.1.4 Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Non-24-hour Sleep-wake Disorder Treatment Sales Value, 2019-2030

5.2.2 North America Non-24-hour Sleep-wake Disorder Treatment Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Non-24-hour Sleep-wake Disorder Treatment Sales Value, 2019-2030

5.3.2 Europe Non-24-hour Sleep-wake Disorder Treatment Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Non-24-hour Sleep-wake Disorder Treatment Sales Value, 2019-2030

5.4.2 Asia Pacific Non-24-hour Sleep-wake Disorder Treatment Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Non-24-hour Sleep-wake Disorder Treatment Sales Value, 2019-2030

5.5.2 South America Non-24-hour Sleep-wake Disorder Treatment Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Non-24-hour Sleep-wake Disorder Treatment Sales Value, 2019-2030

5.6.2 Middle East & Africa Non-24-hour Sleep-wake Disorder Treatment Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Non-24-hour Sleep-wake Disorder Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Non-24-hour Sleep-wake Disorder Treatment Sales Value

6.3 United States

6.3.1 United States Non-24-hour Sleep-wake Disorder Treatment Sales Value, 2019-2030

6.3.2 United States Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Non-24-hour Sleep-wake Disorder Treatment Sales Value, 2019-2030

6.4.2 Europe Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Non-24-hour Sleep-wake Disorder Treatment Sales Value, 2019-2030

6.5.2 China Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type (%), 2023 VS 2030

6.5.3 China Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Non-24-hour Sleep-wake Disorder Treatment Sales Value, 2019-2030

6.6.2 Japan Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Non-24-hour Sleep-wake Disorder Treatment Sales Value, 2019-2030

6.7.2 South Korea Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Non-24-hour Sleep-wake Disorder Treatment Sales Value, 2019-2030

6.8.2 Southeast Asia Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Non-24-hour Sleep-wake Disorder Treatment Sales Value, 2019-2030

6.9.2 India Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type (%), 2023 VS 2030

6.9.3 India Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Teva

7.1.1 Teva Profile

7.1.2 Teva Main Business

7.1.3 Teva Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

7.1.4 Teva Non-24-hour Sleep-wake Disorder Treatment Revenue (US$ Million) & (2019-2024)

7.1.5 Teva Recent Developments

7.2 Mylan

7.2.1 Mylan Profile

7.2.2 Mylan Main Business

7.2.3 Mylan Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

7.2.4 Mylan Non-24-hour Sleep-wake Disorder Treatment Revenue (US$ Million) & (2019-2024)

7.2.5 Mylan Recent Developments

7.3 Nature’s Bounty

7.3.1 Nature’s Bounty Profile

7.3.2 Nature’s Bounty Main Business

7.3.3 Nature’s Bounty Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

7.3.4 Nature’s Bounty Non-24-hour Sleep-wake Disorder Treatment Revenue (US$ Million) & (2019-2024)

7.3.5 Otsuka Pharma (Pharmavite) Recent Developments

7.4 Otsuka Pharma (Pharmavite)

7.4.1 Otsuka Pharma (Pharmavite) Profile

7.4.2 Otsuka Pharma (Pharmavite) Main Business

7.4.3 Otsuka Pharma (Pharmavite) Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

7.4.4 Otsuka Pharma (Pharmavite) Non-24-hour Sleep-wake Disorder Treatment Revenue (US$ Million) & (2019-2024)

7.4.5 Otsuka Pharma (Pharmavite) Recent Developments

7.5 Boiron

7.5.1 Boiron Profile

7.5.2 Boiron Main Business

7.5.3 Boiron Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

7.5.4 Boiron Non-24-hour Sleep-wake Disorder Treatment Revenue (US$ Million) & (2019-2024)

7.5.5 Boiron Recent Developments

7.6 Miers Laboratories

7.6.1 Miers Laboratories Profile

7.6.2 Miers Laboratories Main Business

7.6.3 Miers Laboratories Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

7.6.4 Miers Laboratories Non-24-hour Sleep-wake Disorder Treatment Revenue (US$ Million) & (2019-2024)

7.6.5 Miers Laboratories Recent Developments

7.7 Genexa

7.7.1 Genexa Profile

7.7.2 Genexa Main Business

7.7.3 Genexa Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

7.7.4 Genexa Non-24-hour Sleep-wake Disorder Treatment Revenue (US$ Million) & (2019-2024)

7.7.5 Genexa Recent Developments

7.8 Homeocan

7.8.1 Homeocan Profile

7.8.2 Homeocan Main Business

7.8.3 Homeocan Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

7.8.4 Homeocan Non-24-hour Sleep-wake Disorder Treatment Revenue (US$ Million) & (2019-2024)

7.8.5 Homeocan Recent Developments

7.9 Clinigen Group

7.9.1 Clinigen Group Profile

7.9.2 Clinigen Group Main Business

7.9.3 Clinigen Group Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

7.9.4 Clinigen Group Non-24-hour Sleep-wake Disorder Treatment Revenue (US$ Million) & (2019-2024)

7.9.5 Clinigen Group Recent Developments

7.10 Vanda Pharma

7.10.1 Vanda Pharma Profile

7.10.2 Vanda Pharma Main Business

7.10.3 Vanda Pharma Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

7.10.4 Vanda Pharma Non-24-hour Sleep-wake Disorder Treatment Revenue (US$ Million) & (2019-2024)

7.10.5 Vanda Pharma Recent Developments

8 Industry Chain Analysis

8.1 Non-24-hour Sleep-wake Disorder Treatment Industrial Chain

8.2 Non-24-hour Sleep-wake Disorder Treatment Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Non-24-hour Sleep-wake Disorder Treatment Sales Model

8.5.2 Sales Channel

8.5.3 Non-24-hour Sleep-wake Disorder Treatment Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Nature's Bounty

Otsuka Pharma (Pharmavite)

List of Tables

Table 1. Non-24-hour Sleep-wake Disorder Treatment Market Trends

Table 2. Non-24-hour Sleep-wake Disorder Treatment Market Drivers & Opportunity

Table 3. Non-24-hour Sleep-wake Disorder Treatment Market Challenges

Table 4. Non-24-hour Sleep-wake Disorder Treatment Market Restraints

Table 5. Global Non-24-hour Sleep-wake Disorder Treatment Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Non-24-hour Sleep-wake Disorder Treatment Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Non-24-hour Sleep-wake Disorder Treatment Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Non-24-hour Sleep-wake Disorder Treatment Product Type

Table 9. Key Companies Time to Begin Mass Production of Non-24-hour Sleep-wake Disorder Treatment

Table 10. Global Non-24-hour Sleep-wake Disorder Treatment Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-24-hour Sleep-wake Disorder Treatment as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Non-24-hour Sleep-wake Disorder Treatment Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Non-24-hour Sleep-wake Disorder Treatment Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Non-24-hour Sleep-wake Disorder Treatment Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Non-24-hour Sleep-wake Disorder Treatment Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Region (2019-2024) & (%)

Table 27. Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Non-24-hour Sleep-wake Disorder Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Non-24-hour Sleep-wake Disorder Treatment Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Non-24-hour Sleep-wake Disorder Treatment Sales Value, (2025-2030) & (US$ Million)

Table 31. Teva Basic Information List

Table 32. Teva Description and Business Overview

Table 33. Teva Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

Table 34. Revenue (US$ Million) in Non-24-hour Sleep-wake Disorder Treatment Business of Teva (2019-2024)

Table 35. Teva Recent Developments

Table 36. Mylan Basic Information List

Table 37. Mylan Description and Business Overview

Table 38. Mylan Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

Table 39. Revenue (US$ Million) in Non-24-hour Sleep-wake Disorder Treatment Business of Mylan (2019-2024)

Table 40. Mylan Recent Developments

Table 41. Nature’s Bounty Basic Information List

Table 42. Nature’s Bounty Description and Business Overview

Table 43. Nature’s Bounty Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

Table 44. Revenue (US$ Million) in Non-24-hour Sleep-wake Disorder Treatment Business of Nature’s Bounty (2019-2024)

Table 45. Nature’s Bounty Recent Developments

Table 46. Otsuka Pharma (Pharmavite) Basic Information List

Table 47. Otsuka Pharma (Pharmavite) Description and Business Overview

Table 48. Otsuka Pharma (Pharmavite) Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

Table 49. Revenue (US$ Million) in Non-24-hour Sleep-wake Disorder Treatment Business of Otsuka Pharma (Pharmavite) (2019-2024)

Table 50. Otsuka Pharma (Pharmavite) Recent Developments

Table 51. Boiron Basic Information List

Table 52. Boiron Description and Business Overview

Table 53. Boiron Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

Table 54. Revenue (US$ Million) in Non-24-hour Sleep-wake Disorder Treatment Business of Boiron (2019-2024)

Table 55. Boiron Recent Developments

Table 56. Miers Laboratories Basic Information List

Table 57. Miers Laboratories Description and Business Overview

Table 58. Miers Laboratories Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

Table 59. Revenue (US$ Million) in Non-24-hour Sleep-wake Disorder Treatment Business of Miers Laboratories (2019-2024)

Table 60. Miers Laboratories Recent Developments

Table 61. Genexa Basic Information List

Table 62. Genexa Description and Business Overview

Table 63. Genexa Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

Table 64. Revenue (US$ Million) in Non-24-hour Sleep-wake Disorder Treatment Business of Genexa (2019-2024)

Table 65. Genexa Recent Developments

Table 66. Homeocan Basic Information List

Table 67. Homeocan Description and Business Overview

Table 68. Homeocan Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

Table 69. Revenue (US$ Million) in Non-24-hour Sleep-wake Disorder Treatment Business of Homeocan (2019-2024)

Table 70. Homeocan Recent Developments

Table 71. Clinigen Group Basic Information List

Table 72. Clinigen Group Description and Business Overview

Table 73. Clinigen Group Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

Table 74. Revenue (US$ Million) in Non-24-hour Sleep-wake Disorder Treatment Business of Clinigen Group (2019-2024)

Table 75. Clinigen Group Recent Developments

Table 76. Vanda Pharma Basic Information List

Table 77. Vanda Pharma Description and Business Overview

Table 78. Vanda Pharma Non-24-hour Sleep-wake Disorder Treatment Products, Services and Solutions

Table 79. Revenue (US$ Million) in Non-24-hour Sleep-wake Disorder Treatment Business of Vanda Pharma (2019-2024)

Table 80. Vanda Pharma Recent Developments

Table 81. Key Raw Materials Lists

Table 82. Raw Materials Key Suppliers Lists

Table 83. Non-24-hour Sleep-wake Disorder Treatment Downstream Customers

Table 84. Non-24-hour Sleep-wake Disorder Treatment Distributors List

Table 85. Research Programs/Design for This Report

Table 86. Key Data Information from Secondary Sources

Table 87. Key Data Information from Primary Sources

Table 88. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Non-24-hour Sleep-wake Disorder Treatment Product Picture

Figure 2. Global Non-24-hour Sleep-wake Disorder Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Non-24-hour Sleep-wake Disorder Treatment Sales Value (2019-2030) & (US$ Million)

Figure 4. Non-24-hour Sleep-wake Disorder Treatment Report Years Considered

Figure 5. Global Non-24-hour Sleep-wake Disorder Treatment Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Non-24-hour Sleep-wake Disorder Treatment Revenue in 2023

Figure 7. Non-24-hour Sleep-wake Disorder Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Prescription Drugs Picture

Figure 9. OTC Picture

Figure 10. Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 11. Global Non-24-hour Sleep-wake Disorder Treatment Sales Value Market Share by Type, 2023 & 2030

Figure 12. Product Picture of Hospital Pharmacies

Figure 13. Product Picture of Retail Pharmacies

Figure 14. Product Picture of Other

Figure 15. Global Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 16. Global Non-24-hour Sleep-wake Disorder Treatment Sales Value Market Share by Application, 2023 & 2030

Figure 17. North America Non-24-hour Sleep-wake Disorder Treatment Sales Value (2019-2030) & (US$ Million)

Figure 18. North America Non-24-hour Sleep-wake Disorder Treatment Sales Value by Country (%), 2023 VS 2030

Figure 19. Europe Non-24-hour Sleep-wake Disorder Treatment Sales Value (2019-2030) & (US$ Million)

Figure 20. Europe Non-24-hour Sleep-wake Disorder Treatment Sales Value by Country (%), 2023 VS 2030

Figure 21. Asia Pacific Non-24-hour Sleep-wake Disorder Treatment Sales Value (2019-2030) & (US$ Million)

Figure 22. Asia Pacific Non-24-hour Sleep-wake Disorder Treatment Sales Value by Country (%), 2023 VS 2030

Figure 23. South America Non-24-hour Sleep-wake Disorder Treatment Sales Value (2019-2030) & (US$ Million)

Figure 24. South America Non-24-hour Sleep-wake Disorder Treatment Sales Value by Country (%), 2023 VS 2030

Figure 25. Middle East & Africa Non-24-hour Sleep-wake Disorder Treatment Sales Value (2019-2030) & (US$ Million)

Figure 26. Middle East & Africa Non-24-hour Sleep-wake Disorder Treatment Sales Value by Country (%), 2023 VS 2030

Figure 27. Key Countries/Regions Non-24-hour Sleep-wake Disorder Treatment Sales Value (%), (2019-2030)

Figure 28. United States Non-24-hour Sleep-wake Disorder Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 29. United States Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type (%), 2023 VS 2030

Figure 30. United States Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application (%), 2023 VS 2030

Figure 31. Europe Non-24-hour Sleep-wake Disorder Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 32. Europe Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type (%), 2023 VS 2030

Figure 33. Europe Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application (%), 2023 VS 2030

Figure 34. China Non-24-hour Sleep-wake Disorder Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 35. China Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type (%), 2023 VS 2030

Figure 36. China Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application (%), 2023 VS 2030

Figure 37. Japan Non-24-hour Sleep-wake Disorder Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 38. Japan Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type (%), 2023 VS 2030

Figure 39. Japan Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application (%), 2023 VS 2030

Figure 40. South Korea Non-24-hour Sleep-wake Disorder Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 41. South Korea Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type (%), 2023 VS 2030

Figure 42. South Korea Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application (%), 2023 VS 2030

Figure 43. Southeast Asia Non-24-hour Sleep-wake Disorder Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 44. Southeast Asia Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type (%), 2023 VS 2030

Figure 45. Southeast Asia Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application (%), 2023 VS 2030

Figure 46. India Non-24-hour Sleep-wake Disorder Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 47. India Non-24-hour Sleep-wake Disorder Treatment Sales Value by Type (%), 2023 VS 2030

Figure 48. India Non-24-hour Sleep-wake Disorder Treatment Sales Value by Application (%), 2023 VS 2030

Figure 49. Non-24-hour Sleep-wake Disorder Treatment Industrial Chain

Figure 50. Non-24-hour Sleep-wake Disorder Treatment Manufacturing Cost Structure

Figure 51. Channels of Distribution (Direct Sales, and Distribution)

Figure 52. Bottom-up and Top-down Approaches for This Report

Figure 53. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Sleep Wake Disorder Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Circadian Rhythm Sleep Disorders Market Insights Forecast to 2030

Short Sleep Syndrome Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Sleep Movement Disorder Drug Market Insights Forecast to 2030

Sleep Disorder Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Insomnia Therapy Market Research Report 2025

Global Desynchronosis Treatment Market Insights Forecast to 2030

Global Jet Lag Therapy Pharmaceuticals Market Insights Forecast to 2030

Global Circadian Rhythm Lighting Market Research Report 2024

Global Sleep Disorders Treatment Services Market Research Report 2025

Global Jet Lag Treatment Market Insights Forecast to 2030

Global Time Zone Change Syndrome Treatment Market Insights Forecast to 2030

Global Insomnia Monitoring Equipment Market Insights Forecast to 2030

Global Non Wearable Sleep Tracker Market Research Report 2024

Global Narcolepsy Treatment Market Research Report 2024

Global Sleep Disorder Therapies Market Research Report 2024

Jet Lag Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Home Sleep Screening Non Wearable Devices Market Insights Forecast to 2030

Circadian Lighting Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Digestive System Antacids Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-24T19051

Wed May 21 00:00:00 UTC 2025

Add to Cart

Global Hemostats For Wound Closure Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-19K19445

Wed May 21 00:00:00 UTC 2025

Add to Cart

Global Renal Denervation (RDN) Therapy Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-17S14385

Wed May 21 00:00:00 UTC 2025

Add to Cart

Global Cholesterol HP Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-17C19514

Wed May 21 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions